ImmunityBio
IBRX
62 hedge funds and large institutions have $43.5M invested in ImmunityBio in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 22 reducing their positions, and 9 closing their positions.
736% more call options, than puts
Call options by funds: $117K | Put options by funds: $14K
5% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 22
1.57% less ownership
Funds ownership: 15.71% → 14.14% (-1.6%)
2% less funds holding
Funds holding: 63 → 62 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
22% less capital invested
Capital invested by funds: $56.1M → $43.5M (-$12.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$550K |
| 2 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$427K |
| 3 |
Morgan Stanley
New York
|
+$388K |
| 4 |
Renaissance Technologies
New York
|
+$304K |
| 5 |
VF
Virtu Financial
New York
|
+$203K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.56M |
| 2 |
WCM
Wildcat Capital Management
New York
|
-$1.11M |
| 3 |
AG
Artal Group
Luxembourg
|
-$1.01M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$782K |
| 5 |
BlackRock
New York
|
-$553K |
IBRX Hedge Fund Activity: Q1 2018 in Review
62 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2018, worth a combined $43.5M — down 22% from $56.1M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IBRX and 8 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 21 added.
The largest buyer was Millennium Management, adding an estimated $550K. The largest seller was Fidelity Investments, cutting an estimated $4.56M.
- 62 institutional investors held ImmunityBio (IBRX) as of Q1 2018, down from 63 in Q4 2017.
- Funds reported $43.5M of ImmunityBio stock for Q1 2018, down 22% quarter-over-quarter.
- 8 funds opened new ImmunityBio positions in Q1 2018 and 9 closed out, a net change of -1 holder.
- The largest ImmunityBio buyer in Q1 2018 was Millennium Management, an estimated $550K added.
- The largest ImmunityBio seller in Q1 2018 was Fidelity Investments, an estimated $4.56M sold.
Based on aggregated 13F filings for Q1 2018.